Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.
• Genomic sequencing panels are tests that analyse the DNA of the patient's tumour to look for genetic variants for which there are effective drugs. If the tumour has these variants, treatment can be personalised.
• Today, these tests are only useful in 1 in 20 patients in whom they are applied, because most of the time they are used without following clinical recommendations. This is the finding of a study by the CNIO Breast Cancer Clinical Research Unit.
• The study shows that when clinical recommendations are followed, genomic sequencing panels increase the efficacy of treatments and patient survival.
• The use of these tests is recommended for patients with metastatic colon, lung or melanoma cancer, or rare tumours, or for patients who are going to participate in a clinical trial.
In recent years, the use of genomic sequencing panels in cancer treatment has become widespread. These are tests that search the DNA of the patient s tumor for gene variants for which validated drugs are known, making the treatment more personalized and therefore more effective. They are part of what is known as precision oncology.
New mechanisms underlying this condition, often dubbed "broken heart syndrome," have been suggested from hemodynamic studies, which could lead to new treatment strategies.